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Background: Bipolar disorders (BD) are among the most severe mental disorders with first clinical signs and
symptoms frequently appearing in adolescence and early adulthood. The long latency in clinical diagnosis (and
subsequent adequate treatment) adversely affects the course of disease, effectiveness of interventions and
health-related quality of life, and increases the economic burden of BD. Despite uncertainties about risk constellations
and symptomatology in the early stages of potentially developing BD, many adolescents and young adults seek help,
and most of them suffer substantially from symptoms already leading to impairments in psychosocial functioning in
school, training, at work and in their social relationships. We aimed to identify subjects at risk of developing BD and
investigate the efficacy and safety of early specific cognitive-behavioural psychotherapy (CBT) in this subpopulation.
Methods/Design: EarlyCBT is a randomised controlled multi-centre clinical trial to evaluate the efficacy and safety of
early specific CBT, including stress management and problem solving strategies, with elements of mindfulness-based
therapy (MBT) versus unstructured group meetings for 14 weeks each and follow-up until week 78. Participants are
recruited at seven university hospitals throughout Germany, which provide in- and outpatient care (including
early recognition centres) for psychiatric patients. Subjects at high risk must be 15 to 30 years old and meet the
combination of specified affective symptomatology, reduction of psychosocial functioning, and family history
for (schizo)affective disorders. Primary efficacy endpoints are differences in psychosocial functioning and defined
affective symptomatology at 14 weeks between groups. Secondary endpoints include the above mentioned
endpoints at 7, 24, 52 and 78 weeks and the change within groups compared to baseline; perception of, reaction
to and coping with stress; and conversion to full BD.
Discussion: To our knowledge, this is the first study to evaluate early specific CBT in subjects at high risk for BD.
Structured diagnostic interviews are used to map the risk status and development of disease. With our study, the level
of evidence for the treatment of those young patients will be significantly raised.
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Bipolar disorders (BD) are among the most severe men-
tal disorders. Lifetime prevalence estimates range from 1
to 5% [1-5]. They are associated with a recurrent or
chronic course, insufficient clinical response, and psy-
chosocial impairment in a substantial number of pa-
tients. First clinical signs and symptoms frequently
appear in adolescence and early adulthood (median age
at disease onset 17.5 years) [6-8]. Usually there is, how-
ever, a long lag before the correct diagnosis is estab-
lished and treatment is often delayed for many years
[6,7,9-13]. Delayed treatment and an increasing number
of illness episodes have been associated with a decreased
probability of response to treatment [14] and an ad-
verse course of illness [15,16]. The combination of long
undetected illness with no or inadequate treatment
and significant psychosocial impairment renders early
identification and intervention a vital role in disease
management.
To date, there has been relatively little research into
early identification and intervention in subjects at risk
for BD. First at-risk criteria based on clinical presenta-
tion and/or family history have been proposed and
pilot evaluation data are available [17,18]. Moreover,
structured diagnostic instruments for the prospective
identification of at-risk constellations for BD have been
developed and are currently validated [19,20]. These
structured measures are applied in the present study.
Regarding treatment in these at-risk states, in a recent
systematic review [21] we identified three studies: an
exploratory, controlled study of multi-family psycho-
educational psychotherapy from the group of Fristad
and colleagues [22], an open, uncontrolled easibility
study of family-focussed therapy by Miklowitz et al.
[23] and the subsequent randomised controlled study
of the same group [24]. Treatment with the studied inter-
ventions (in addition to treatment as usual, including
psychopharmacology) showed a potential for symptom
reduction and prevention of conversion to BD and a
significantly faster recovery from initial mood symp-
toms and more time in remission during follow-up
compared to control conditions. The results, however,
have to be interpreted with caution, because of the
small sample sizes, permission of medication treat-
ments in the intervention and control groups in all
studies, and the lack of a control group or data on con-
version in one study. Until now, there is no data on
the efficacy of early cognitive-behavioural psychother-
apy (CBT) in high-risk subjects for BD. In current clin-
ical routine, neither screening for at-risk states nor
specialised diagnostic processes are implemented, and
even in cases that present with significant affective
symptoms, no specific intervention is routinely offered
before the full disorder manifests.Objectives/hypotheses
CBT has been shown to be effective in BD (see [25,26]).
Previous research suggested that, although there was no
significant difference in overall recurrence rates, CBT is
more effective than treatment as usual in bipolar pa-
tients with few, as compared to those with many, epi-
sodes in their history [27]. We therefore hypothesise
that the intervention might be more effective in the early
stages of disease and even more so in the prodromal
phase.
We therefore aimed to conduct a prospective randomised
controlled trial to compare an experimental intervention
(early specific CBT including stress management and prob-
lem solving strategies with elements of mindfulness-based
therapy (MBT) in a group setting) against unstructured
group meetings. We hypothesised that subjects randomly
allocated to the experimental intervention show less psy-
chosocial impairment and specified affective symptomatol-
ogy at 14 weeks compared to subjects receiving the control
intervention.
Methods/Design
Design of the study
This is a randomised controlled multi-centre clinical trial
to evaluate the efficacy and safety of a specific CBT for
young people at-risk for BD versus unstructured group
meetings for 14 weeks each with long-term follow-up until
week 78. Figure 1 summarises the trial flow. Study subjects,
outcome assessors, and the statistician are blinded to treat-
ment allocation. The study is conducted according to good
clinical practice (GCP) standards and has been approved
by the responsible local ethical committees.
Description of intervention and control condition
In the absence of a published manual, an intervention
was specifically designed to meet the needs of the bipo-
lar high-risk clientele (BEsT (be)for(e) Bipolar, © C Marx,
K Leopold and A Pfennig 2010). It consists of specific
CBT, including stress management and problem solving
strategies with elements of MBT in a group setting. The
newly developed intervention was based on the manual
‘Cognitive psychoeducational therapy for bipolar disor-
ders’ by Schaub et al. [28]; modules for stress manage-
ment and problem solving strategies from the manual
‘Kognitiv-verhaltenstherapeutisches Behandlungsmanual’
by Meyer and Hautzinger [29] were integrated. Add-
itionally, mindfulness exercises from MBT [30] are used.
The aforementioned manuals were chosen by means of
aptitude for the purpose of the intervention and avail-
ability of validation data. Modules were adapted to the
needs of at-risk subjects similarly to the approach described
by Bechdolf and Juckel [31] as some modules conceptua-
lised for patients with full manifestation were weakened
and terms of probability/risk were emphasised. Treatment
Figure 1 Trial flow. Legend: CBT (cognitive-behavioural psychotherapy), FU (follow-up).
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education about mental illnesses, and BD in particular,
including treatment options, handling of early warning
signs and crisis planning for prophylaxis, structuring
of activities, cognitive strategies, and sensitisation for a
balanced life rhythm. The control condition consists of un-
structured group meetings where therapists are instructed
to avoid therapeutic measures in any way possible. Both in-
terventions are applied in groups of four to five subjects
and in the same frequency and duration with 14 sessions
each of 90 minutes within 14 weeks (one per week). To in-
crease transparency and documentation as well as for ana-
lysis and comparability, sessions are videotaped.
Setting and participants
Study participants were initially recruited at five, now at
seven participating university centres which provide in-
and outpatient care for patients with unipolar depressive
and bipolar disorders (Department of Psychiatry and
Psychotherapy, University Hospital Carl Gustav Carus
Dresden; Department of Psychiatry, Ruhr University
Hospital Bochum; Department of Psychiatry and Psycho-
therapy, University Medical Center Hamburg-Eppendorf;
Department of Child and Adolescent Psychiatry and Psy-
chotherapy, LWL University Hospital Hamm; Department
of Psychiatry, University Hospital Cologne; Department
of Psychiatry and Psychotherapy, University Hospital
Würzburg, Department of Psychiatry, Psychosomatics
and Psychotherapy, Charité-University Medicine, CCM;
all Germany). Most of them additionally run early recog-
nition centres for psychoses and/or affective disorders.
Key inclusion criteria for subjects include:
 Positive family history for affective and/or schizoaffective
disorders (first and/or second degree relative)
 Reduction in psychosocial functioning/coping with
demands of daily living (measured by the SocialInterview Schedule, SIS, [32], German version: [33])
in the last 12 months compared to the previous
12 months
 Specified affective symptomatology (sub-threshold
mania and/or at least sub-threshold depression with
cyclothymic features and/or cyclothymic features,
definitions see below) (measured by the Early Phase
Inventory for bipolar disorders (EPIbipolar, ©Pfennig
and Leopold 2010, [19]) and the Bipolar Prodrome
Symptom Scale (BPSS)-Prospective (©C Correll
2007, [20]) in the last 12 months compared to the
previous 12 months
 Aged 15 to 30 years
 Language capacity to take part in the trial
 Written informed consent to participate in the
study.
Definitions of specified affective symptomatology are
similar to those proposed by Bechdolf et al. [17]: sub-
threshold mania is defined as a period of at least two
consecutive days of abnormally and persistently elevated,
expansive or irritable mood plus at least two of the fol-
lowing criteria: inflated self-esteem or grandiosity, de-
creased need for sleep, more talkative than usual or
pressure to keep talking, flight of ideas or subjective ex-
perience that thoughts are racing, distractibility, in-
creased goal-directed activity or psychomotor agitation.
At least sub-threshold depression is defined as depressed
mood or loss of interest or pleasure plus at least two of
the following criteria: fatigue or loss of energy, feelings of
worthlessness or excessive or inappropriate guilt, insom-
nia or hypersomnia nearly every day, psychomotor re-
tardation or agitation, diminished ability to think or
concentrate, recurrent thoughts of death/recurrent sui-
cidal ideation or significant weight loss over a period
of at least one week. Cyclothymic features are defined
as numerous episodes with sub-threshold manic symptoms
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numerous episodes with depressive symptoms.
Key exclusion criteria include:
 A history of treated or untreated manic episode of at
least four days duration (Structured Clinical
Interview for Diagnostic and Statistical Manual of
Mental Disorders, 4th edition (DSM-IV) Disorders,
SCID, in German: [34])
 A history of treated or untreated psychosis of at
least seven days duration (SCID)
 Main symptomatology must not be present solely
within the context of personality disorder or
cyclothymia (SCID)
 Organic brain disorder
 Acute suicidality
 Severe, unstable medical condition (for example,
cancer, neurological diseases)
 Intake of psychotropic medication (only medication
for sleep disturbances and a stable antidepressant
medication with serotonin reuptake inhibitors
(SSRIs), venlafaxine, duloxetine, mirtazapine or
valdoxan (stable means intake for at least eight
weeks) are allowed, all other drug doses must be
tapered-down and stopped before randomisation).
Rationale for choosing the presented inclusion and ex-
clusion criteria are as follows. First degree relatives of af-
fected individuals have a ten-fold increased risk to also
develop the disease compared to relatives of unaffected
controls [35]. Twin and adoption studies have provided
compelling evidence for heritable factors playing a major
role in the pathogenesis of BD (see [36]). A genetically
enriched population with first affective symptoms that
already impact psychosocial functioning seemed to us
the best way to identify subjects at high risk for develop-
ing BD. Participants must not already be diagnosed as
having unipolar or bipolar affective disorders but can be
diagnosed as having cyclothymia, attention deficit/hyper-
activity disorder (ADHD), personality disorder or psychosis
of less than seven days duration, if the symptomatology is
not explained solely by this diagnosis. In view of the often
unspecific presentation of high-risk subjects, this ensures
reduction of false-negative recruitment, while at the same
time of course the risk for false-positive enrolment is in-
creased. The pilot findings by Bechdolf et al. [17,18] which
indicated conversion rates to four days of mania in up to
30% within 12 months, depending on the criteria applied,
support this approach of inclusion criteria definition. The
diagnostic procedure comprises using the SCID plus the
result of a consensus board of two clinical psychiatrists per
centre.
Subjects in both treatment groups are allowed to use
unstructured consultations with their usual treatingphysician at any time. After the intervention period,
subjects in both groups are allowed to use unstruc-
tured psychotherapy sessions and psychopharmacother-
apy if needed (restricted to intermittent symptomatic
treatment of unspecific symptoms such as sleep distur-
bances and anxiety/agitation administered no longer than
seven days). As mentioned, a stable antidepressant medi-
cation with SSRI, venlafaxine, duloxetine, mirtazapine or
valdoxan (stable means intake for at least eight weeks) is
allowed at randomisation and can be prolonged during
the study. Formal, structured psychotherapy and psycho-
pharmacotherapy other than described before results in
study drop-out.
As mentioned in the inclusion criteria, written in-
formed consent is obtained from each subject after thor-
ough information about the study has been provided.
Outcome measures
Primary efficacy endpoints:
 Psychosocial functioning/coping with demands of
daily living (SIS) at 14 weeks
 Specified affective symptomatology (Hamilton
Rating Scale for Depression (HAMD, [37]), Young
Mania Rating Scale (YMRS, [38]), EPIbipolar, BPSS)
at 14 weeks
Key secondary endpoints:
 SIS at 7, 24, 52 and 78 weeks
 Mini version of the International Classification of
Functioning, Disability and Health for Mental
Disorders (MINI-ICF-P, [39,40]) at 7, 14, 24, 52 and
78 weeks
 Specified affective symptomatology (HAMD, YMRS,
EPIbipolar, BPSS) at 7, 24, 52 and 78 weeks
 Perception of, reaction to and coping with stress:
Alltags-Belastungs-Fragebogen (ABF, [41]), Trierer
Inventar zum chronischen Stress (TICS, [42]),
Stress-Reaktivitäts-Skala (SRS, [43]), Fragebogen
zum Umgang mit Belastungen im Verlauf (UBV,
[44]), Fragebogen zur Erfassung von Ressourcen und
Selbstmanagementfähigkeiten (FERUS, [45]) at 7, 14,
24, 52 and 78 weeks
 Development of bipolar disorders at 52 and
78 weeks (SCID).
Assessment of safety: structured assessment of adverse
events (GCP standard, interview: description of type, se-
verity and relation to intervention). See Table 1 for an
overview of instruments applied.
Rationale for choosing the presented outcome mea-
sures are as follows. We chose coping with demands of
daily living as one primary outcome measure as it is a
Table 1 Instruments applied at individual study visits
Time Baseline FU 1 FU 2 FU 3 FU 4 FU 5
Instruments Wk -1 Wk 7 Wk 14 Wk 24 Wk 52 Wk 78
SIS X X X X X X
MINI-ICF-P X X X X X X
HAMD X X X X X X
YMRS X X X X X X
EPIbipolar X X X X X X
BPSS X X X X X X
ABF X X X X X X
TICS X X X X X X
SRS X X X X X X
UBV X X X X X X
FERUS X X X X X X
SCID X X X
Legend: FU, follow-up; Wk, week; SIS, Social Interview Schedule, English
version: [32], German version: [33]); MINI-ICF-P, Mini version of the International
Classification of Functioning, Disability and Health for Mental Disorders, [39,40];
HAMD, Hamilton Depression Symptom Scale 17 item version, [37]; YMRS, Young
Mania Rating Scale, [38]; EPIbipolar, Early Phase Inventory for bipolar disorders,
©Pfennig and Leopold 2010, [19]; BPSS, Bipolar Prodrome Symptom Scale-
Prospective, ©C Correll 2007, [20]; ABF, Alltags-Belastungs-Fragebogen, [41]; TICS,
Trierer Inventar zum chronischen Stress, [42]; SRS, Stress-Reaktivitäts-Skala, [43];
UBV, Fragebogen zum Umgang mit Belastungen im Verlauf, [44]; FERUS,
Fragebogen zur Erfassung von Ressourcen und Selbstmanagementfähigkeiten,
[45]; SCID, Structured Clinical Interview for DSM-IV Disorders, in German: [34]. The
baseline time is week minus 1.
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that in turn highly influences the long-term outcome of
the disorder. Our study population consists of subjects
at high risk for developing BD; they do not fulfill the
diagnosis (yet) but already show impairment of psycho-
social functioning. Improving this should have a great
impact on the course of the disease development either
by postponing/alleviating or even preventing the full-
blown disorder. Additionally, we use the change in affective
symptomatology as a primary endpoint since psychosocial
functioning is only in part explained by psychiatric
symptomatology.
To get an idea about adherence on the therapist’s part
to the treatment manual or instructions regarding the
control group setting, videotaped treatment sessions which
have been developed based on the German adapted
version of the Cognitive Therapy Scale for Psychosis
[46] by Wittorf et al. [47], will be reviewed. Adherence
on the subject’s part is assessed by checking on partici-
pation in the sessions as well as home work comple-
tion in the active intervention groups.
Blinding and methods against bias
An independent statistician uses a centrally computer-
generated block-designed randomisation procedure strati-
fied by centre. Only the principal investigator of the study
(AP) and the psychotherapist of the individual centre arenotified of the randomisation result; subjects and outcome
assessors are kept blinded. The statistician who will later
analyse the study results is kept blinded throughout the
whole study.
An intensive three days training of GCP, study proce-
dures and applied instruments was provided to psycho-
therapists and raters before onset of the study to minimise
differences between centres. Regular trainings are pro-
vided throughout the study. All group sessions (in the
intervention and control groups) are videotaped and
stored for analysis. The trial is managed with help of
the departmental clinical trial centre.
To ensure the performance according to the study
protocol and the quality of the study monitoring is per-
formed in each study centre at appointed time intervals
and as needed (at least per centre once at initiation of
the study, once after the first subject was randomised,
once after 1/3, 2/3 and 3/3 of subjects were recruited,
and once when the last subject completed the study),
the monitoring process is performed according to pre-
pared standard operating procedures (SOPs). The moni-
tor checks completeness and plausibility of the data and
aligns the study data to the original data (Source Data
Verification). This is accomplished by accessing the ori-
ginal subjects’ charts; the subjects will give their permis-
sion to that procedure within the informed consent
form. The monitor ensures the basic claim of integrity
and protection of the subjects’ privacy. If not all data are
examined, the monitor must justify that procedure and
must pull a proper random sample for the check.
Supervision of the trial is present in the form of a sci-
entific advisory board including members especially ex-
perienced in assuring data quality and safety. They also
supervised the development of the application protocol
and the progress of the trial including decision making
on whether to perform interim analyses or modify/stop
the trial in cases of unforeseen problems arising.
Power
Sample size for the ANCOVA will be approximated with
the two-sided unpaired t-test. The primary outcome
measure is the difference in the adapted overall social
maladjustment score. Here, the number of items in the
categories M and S with a rating of 2, 3 or 4 is divided
by the number of applicable items in the categories M
and S. With an estimated effect size of about 0.5, a
sample size of 2 times 50 patients is required to show
this difference with a power of 80% and an alpha of 5%
(calculated with G*Power 3.1.2).
We assume that the compliance will be relatively good
here since the intervention does not result in major side
effects and the subjects already experience symptoms.
However, we assume conservatively that there will be
about a 30% drop-out rate, an estimate that was accounted
Table 2 Ethics committees of the participating study
centres
Ethics committee Reference number
Medizinische Fakultät, TU Dresden EK 60022010
Medizinische Fakultät, Ruhr University Bochum 3757-10
Ärztekammer Hamburg MC-196/10
Medizinische Fakultät, Ruhr University Bochum 3782-10
Medizinische Fakultät der Universität zu Köln 10-164
Medizinische Fakultät, University Würzburg 204/12_z
Ethikkommission der Charité Berlin EA1/233/12
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that drop out of the study will last for the planned duration
of the study.
Statistical analysis
Efficacy: two-group comparison of the psychosocial
functioning/coping with demands of daily living (SIS,
MINI-ICF-P), specified affective symptomatology in-
cluding mood swings (HAMD, YMRS, EPIbipolar, BPSS-
P) and difference in perception of, reaction to and coping
with stress (ABF, TICS, SRS, UBV, FERUS) at 7, 14, 24, 52
and 78 weeks with baseline values as covariates. In all
cases, the 14-week value is the primary time-point of
interest. A repeated measures analysis will be carried out
as a secondary result.
Description of the primary efficacy analysis: ANCOVA
with SIS at 14 weeks and separately with specified affective
symptomatology at 14 weeks as dependent variable and
baseline SIS, affective symptomatology, centre, age, sex,
education and group as covariates. We will also look into
influence of the therapist on results by additionally includ-
ing that variable, if not highly correlated with the variable
centre, into the ANCOVA. Population: intention-to-
treat (ITT) analysis with last observation carried for-
ward (LOCF) in case of missing values.
Secondary endpoints:
 Difference between the groups in MINI-ICF-P at 7,
14, 24, 52 and 78 weeks with baseline values as
covariates
 Change in specified affective symptomatology
including mood swings at 7, 24, 52 and 78 weeks
compared to baseline within each group
 Difference between the groups in perception of,
reaction to and coping with stress at 7, 14, 24, 52
and 78 weeks with baseline values as covariates
 Difference between the groups in SIS at 7, 24, 52
and 78 weeks with baseline values as covariates
 Difference between the groups in rates of developing
bipolar disorders at 52 and 78 weeks
Safety: assessment of frequency and type of unwanted
effects at 7, 14, 24, 52 and 78 weeks compared to baseline
within the groups and difference between the groups.
The study was approved by the respective ethics com-
mittees of all participating study centres (see Table 2).
Discussion
To our knowledge, this is the first study to evaluate early
specific cognitive-behavioural psychotherapy in subjects
at high risk for BD. We hypothesise that subjects ran-
domly allocated to early specific CBT, including stress
management and problem solving strategies with ele-
ments of MBT in a group setting, show less reduction inpsychosocial functioning and less specified affective
symptoms at 14 weeks compared to subjects receiving
unstructured group meetings.Limitations
One possible limitation of external validity relates to re-
cruitment in university hospitals in urban areas of Germany
and selection of patients that utilise the healthcare system
or an early recognition centre. People who do not seek
(medical) advice and help may show different characteris-
tics and worse treatment effects.
Diagnostic measures in early stages of disease develop-
ment may show limited precision. The predictive validity
of the used at-risk state definitions are currently assessed
in validation studies (for example, [20]). Consequences
of false positive ‘diagnoses’ may result in additional psy-
chosocial impairment, including worry about possible
psychiatric disease and unneeded treatment causing pre-
ventable adverse drug reactions and/or adverse effects of
interventions. However, CBT as a non-pharmacological
intervention with a low risk of adverse events seems to
be appropriate from the risk-benefit perspective.
The follow-up time of the study is restricted to 78 weeks
per individual, which will not be long enough to detect all
cases of conversion to manifest disorder. Each participat-
ing centre agreed to extend the follow-up time to as long
as possible within their clinical or early recognition centre
routine.
The therapeutic manual was only developed shortly
before starting the study, so its efficacy had not been
previously assessed. Feasibility was tested in the early
recognition centre in Dresden; however, use in a multi-
centre study is only practiced within the present study.
Naturally, the therapist can not be blinded to type of
intervention. The subjects are kept blinded and are only
sketchily informed about the content and design of the
intervention to be studied.
We decided against a third study arm providing a
wait-list control condition. Therefore we cannot measure
the effect of meeting in a group per se.
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cesses were established and interconnections between
departments and early detection services with local ser-
vices and each other were strengthened. Continuous
outreach work is performed.
Strengths
The study has several major strengths: the high-risk sta-
tus is assessed and followed-up by the currently relevant
diagnostic instruments available to the investigators.
Also, the study is timely: treatment options for the
high-risk clientele are needed with subjects suffering
from impairment. Here, early on, one strategy is scien-
tifically assessed for efficacy and safety. In a rando-
mised controlled fashion with blinded subjects, outcome
assessors and statistician, the control condition is matched
as far as possible to the intervention with regard to fre-
quency and duration, group character and participation of
a trained psychologist or psychotherapist. Trainings and
monitoring for therapists and raters are conducted on a
regular basis.
The multi-centre character of the study increases sam-
ple size and generalizability of the results. The cooperat-
ing centres in the study are leading clinical and research
centres for high-risk individuals for psychosis and BD. In
2009, they founded the ‘Network for Early Recognition
and Intervention in Bipolar Disorders’ (NERIBID, [48]).
The aim of the network is to cooperatively develop and
perform research projects and to develop clinical and re-
search standards for our centres.
Relevance of study for clinical practice and future
research
Our approach to identify patients with a positive family
history in potentially early stages of BD is comparable to
that in high-risk subjects for psychosis. In the present
study, clinical presentation, impairment of psychosocial
functioning, and family history is combined to define
persons at risk of a significant conversion risk.
Studies show that cognitive-behavioural psychotherapy
(CBT) is effective in patients with BD in reducing symp-
tomatology. Scott et al. [27] showed that although there
was no significant difference in overall recurrence rates,
CBT was more effective than treatment as usual in pa-
tients with few compared to those with many recurrent
bipolar episodes in their history. We therefore suggest
that the intervention might be more effective in the early
stages of disease and so even more in the prodromal
phase. In persons at risk for psychosis, CBT was shown
to be effective in alleviating symptomatology. The transi-
tion risk was reduced as long as the intervention (psycho-
pharmacological and psychotherapeutic) could reduce the
symptomatology. After the end of the intervention how-
ever, general transition rates increased and then almostequalled that of the group without intervention; see
[49-53]. There were however, as stated above, enduring
effects of CBT in that the likelihood of being pre-
scribed antipsychotics in the three-year follow-up was
reduced ([50]). Interestingly, in the group of subjects
with psychological vulnerabilities targeted by the inter-
vention, the transition risk to psychosis was also sig-
nificantly reduced [49,50]. In full-blown schizophrenia,
of course, CBT without psychopharmacology would be
not effective enough [54].
Additionally, we suggest that the components of the
studied intervention tackle symptomatology associated with
the factors that influence components of the vulnerability-
stress-system (for example, sleep regulation, stress manage-
ment and handling of personality features) and, therefore,
should be best suited to alleviate/postpone or even prevent
onset/conversion to BD. Most importantly, evidence of the
effectiveness and adverse events of CBT in subjects at high
risk for BD is missing so that our study will answer this
clinically relevant question regardless of the study results.
If efficacy of early specific CBT can be demonstrated
by our trial, the level of evidence of the treatment of
subjects at high risk for BD will be significantly raised.
Subsequently, future research should adopt and evaluate
the effectiveness of such a tailored intervention in less
highly-selected populations in routine care. The results
of the proposed study could be used to establish pre-
ventive strategies for BD that are adequate from the
risk-benefit perspective.
Trial status
Ongoing, start of recruitment: August 2010, first patient:
October 2010, 50% randomised: March 2013.
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analysis; LOCF: last observation carried forward; MBT: mindfulness-based therapy;
MINI-ICF-P: Mini version of the International Classification of Functioning, Disability
and Health for Mental Disorders; NERIBID: Network for Early Recognition and
Intervention in Bipolar Disorders; SCID: Structured Clinical Interview for DSM-IV
Disorders.
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